The Experts below are selected from a list of 513 Experts worldwide ranked by ideXlab platform
Dick Van Soolingen - One of the best experts on this subject based on the ideXlab platform.
-
synergistic activity of rifampicin and ethambutol against slow growing nontuberculous mycobacteria is currently of questionable clinical significance
International Journal of Antimicrobial Agents, 2013Co-Authors: Jakko Van Ingen, Wouter Hoefsloot, Martin J Boeree, Johan W Mouton, Dick Van SoolingenAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n = 5), Mycobacterium chimaera (n = 6), Mycobacterium intracellulare (n = 4), Mycobacterium xenopi (n = 4), Mycobacterium malmoense (n = 3) and Mycobacterium simiae (n = 2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index ≤ 0.5. Rifampicin and ethambutol showed synergistic activity against the majority of M. avium (4/5), M. chimaera (5/6) and M. intracellulare (3/4) isolates and 1 of 2 eligible M. malmoense isolates. No synergistic activity was measured against M. xenopi and M. simiae. Synergy was neither universal for all species nor for all isolates of one species; it thus needs to be tested for rather than assumed. Even if this synergy exists in vivo, it is questionable whether the MICs to the combined drugs can be overcome by the drug exposure attained by current regimens at the recommended dosages. New dosing strategies for rifampicin and ethambutol should be studied to increase the exposure to these drugs and thus maximise their impact.
-
Mycobacterium riyadhense sp nov a non tuberculous species identified as Mycobacterium tuberculosis complex by a commercial line probe assay
International Journal of Systematic and Evolutionary Microbiology, 2009Co-Authors: Jakko Van Ingen, Martin J Boeree, Sahal Alhajoj, Fahad Alrabiah, Mimount Enaimi, Rina De Zwaan, Enrico Tortoli, Richard Dekhuijzen, Dick Van SoolingenAbstract:A non-chromogenic, slowly growing Mycobacterium strain was isolated from a maxillary sinus lavage from a symptomatic patient in Riyadh, Saudi Arabia. It was initially identified as a member of the Mycobacterium tuberculosis complex by a commercial line-probe assay. Its 16S rRNA, hsp65 and rpoB gene and 16S-23S internal transcribed spacer sequences were unique; phylogenetic analysis based on the 16S rRNA gene sequence groups this organism close to Mycobacterium szulgai and Mycobacterium malmoense. Its unique biochemical properties and mycolic acid profile support separate species status. We propose the name Mycobacterium riyadhense sp. nov. to accommodate this strain. The type strain is NLA000201958(T) (=CIP 109808(T) =DSM 45176(T)).
Jakko Van Ingen - One of the best experts on this subject based on the ideXlab platform.
-
Dissemination of localized Mycobacterium malmoense infection in an immunocompromised patient
Elsevier, 2018Co-Authors: Sanne M.h. Zweijpfenning, Lydia Schipper, Vincent A.m. Duurkens, Joop B. Harbers, Jakko Van Ingen, Wouter HoefslootAbstract:A 75-year-old woman with a history of immunosuppressive treatment for rheumatoid arthritis and non-Hodgkin lymphoma, was referred to our reference centre for treatment of tenosynovitis caused by Mycobacterium malmoense, which had disseminated due to immunosuppressive therapy. This rare diagnosis was made after years of treatment for supposed rheumatoid arthritis. The patient presented with relapsing tenosynovitis with wounds on her right middle finger and wounds on her left lower leg, despite 3 months of adequate therapy (rifampicin + ethambutol + clarithromycin). Therapy was intensified with amikacin, clofazimine, moxifloxacin, and interferon-gamma due to the lack of response. Amputation of the right middle finger was necessary due to advanced disease. Treatment was further complicated by a paradoxical reaction, requiring prednisone treatment, which ultimately led to cure. Keywords: Disseminated Mycobacterium malmoense infection, Non-tuberculous mycobacteria, Paradoxical reaction, Immunosuppressive medicatio
-
synergistic activity of rifampicin and ethambutol against slow growing nontuberculous mycobacteria is currently of questionable clinical significance
International Journal of Antimicrobial Agents, 2013Co-Authors: Jakko Van Ingen, Wouter Hoefsloot, Martin J Boeree, Johan W Mouton, Dick Van SoolingenAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n = 5), Mycobacterium chimaera (n = 6), Mycobacterium intracellulare (n = 4), Mycobacterium xenopi (n = 4), Mycobacterium malmoense (n = 3) and Mycobacterium simiae (n = 2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index ≤ 0.5. Rifampicin and ethambutol showed synergistic activity against the majority of M. avium (4/5), M. chimaera (5/6) and M. intracellulare (3/4) isolates and 1 of 2 eligible M. malmoense isolates. No synergistic activity was measured against M. xenopi and M. simiae. Synergy was neither universal for all species nor for all isolates of one species; it thus needs to be tested for rather than assumed. Even if this synergy exists in vivo, it is questionable whether the MICs to the combined drugs can be overcome by the drug exposure attained by current regimens at the recommended dosages. New dosing strategies for rifampicin and ethambutol should be studied to increase the exposure to these drugs and thus maximise their impact.
-
Mycobacterium riyadhense sp nov a non tuberculous species identified as Mycobacterium tuberculosis complex by a commercial line probe assay
International Journal of Systematic and Evolutionary Microbiology, 2009Co-Authors: Jakko Van Ingen, Martin J Boeree, Sahal Alhajoj, Fahad Alrabiah, Mimount Enaimi, Rina De Zwaan, Enrico Tortoli, Richard Dekhuijzen, Dick Van SoolingenAbstract:A non-chromogenic, slowly growing Mycobacterium strain was isolated from a maxillary sinus lavage from a symptomatic patient in Riyadh, Saudi Arabia. It was initially identified as a member of the Mycobacterium tuberculosis complex by a commercial line-probe assay. Its 16S rRNA, hsp65 and rpoB gene and 16S-23S internal transcribed spacer sequences were unique; phylogenetic analysis based on the 16S rRNA gene sequence groups this organism close to Mycobacterium szulgai and Mycobacterium malmoense. Its unique biochemical properties and mycolic acid profile support separate species status. We propose the name Mycobacterium riyadhense sp. nov. to accommodate this strain. The type strain is NLA000201958(T) (=CIP 109808(T) =DSM 45176(T)).
Soolingen D. Van - One of the best experts on this subject based on the ideXlab platform.
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton J.w., Soolingen D. VanAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
'Elsevier BV', 2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton † J.w., Soolingen D. VanAbstract:Contains fulltext : 117716.pdf (Publisher’s version ) (Closed access)A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Isolation of mycobacteria other than Mycobacterium avium from porcine lymph nodes.
'Elsevier BV', 2010Co-Authors: Ingen, J. Van, Wisselink H.j., Solt-smits, C.b. Van, Boeree M.j., Soolingen D. VanAbstract:Contains fulltext : 87901.pdf (publisher's version ) (Closed access)Mycobacterium avium causes lymphadenitis in pigs. This presents an economical burden, as these pigs meat is considered inappropriate for consumption. In humans, lymphadenitis due to nontuberculous mycobacteria (NTM) primarily affects children and is caused by a variety of NTM, though M. avium predominates. Mycobacterial culture was undertaken on lymph nodes of 107 slaughter pigs from a single pig farm. A high number of pigs with mycobacterial lymphadenitis were identified by culture. A commercial line probe assay and 16S rDNA gene sequencing were used to assess the frequency of disease due to mycobacteria other than M. avium. Forty-five pigs had mandibular lymph node samples yielding mycobacteria in culture. The majority yielded M. avium (39; 87%) only. One yielded M. avium and Mycobacterium palustre, five yielded only NTM other than M. avium (2yielded Mycobacterium malmoense, 1Mycobacterium bohemicum, 1Mycobacterium heckeshornense and a possibly novel species related to Mycobacterium scrofulaceum, and 1 grew a possibly novel species related to M. palustre). Several NTM species other than M. avium were cultured from porcine lymph nodes. The species distribution shows interesting parallels with human NTM lymphadenitis. Molecular typing and environmental sampling studies are required to identify the sources of these infections
-
Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.
'European Respiratory Society (ERS)', 2009Co-Authors: Hoefsloot W., Ingen, J. Van, Boeree M.j., W.c.m. De ,lange, Dekhuijzen P.n.r., Soolingen D. VanAbstract:Uncertainty exists about the clinical relevance of Mycobacterium malmoense isolation, especially in pulmonary samples. We therefore determined clinical relevance, treatment and outcome of M. malmoense isolation in The Netherlands. A retrospective medical file study was conducted for all patients in The Netherlands from whom Mycobacterium malmoense had been isolated between January 2002 and January 2006. Diagnostic criteria for nontuberculous mycobacterial (NTM) disease published by the American Thoracic Society (ATS) were used to determine clinical relevance. Treatment was compared with guidelines published by the British Thoracic Society. In total, 51 patients were found from whom M. malmoense was isolated. Of these, 40 (78%) patients had pulmonary isolates and 32 (80%) of them met the ATS diagnostic criteria. Cavitary disease was most common (n = 28; 88%). Patients with pulmonary disease were mostly males, with an average age of 56 yrs and pre-existing chronic obstructive pulmonary disease. Cervical lymphadenitis was the most common extrapulmonary disease type. Adherence to treatment guidelines was poor. A good clinical response to treatment was observed in 70% and 73% of patients treated for pulmonary and extrapulmonary disease, respectively. In conclusion, M. malmoense is a clinically highly relevant NTM in The Netherlands causing serious pulmonary morbidity. Adherence to treatment guidelines is not satisfactory
-
Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.
'European Respiratory Society (ERS)', 2009Co-Authors: Hoefsloot W., Ingen, J. Van, Boeree M.j., W.c.m. De ,lange, Dekhuijzen P.n.r., Soolingen D. VanAbstract:Contains fulltext : 79656.pdf (publisher's version ) (Closed access)Uncertainty exists about the clinical relevance of Mycobacterium malmoense isolation, especially in pulmonary samples. We therefore determined clinical relevance, treatment and outcome of M. malmoense isolation in The Netherlands. A retrospective medical file study was conducted for all patients in The Netherlands from whom Mycobacterium malmoense had been isolated between January 2002 and January 2006. Diagnostic criteria for nontuberculous mycobacterial (NTM) disease published by the American Thoracic Society (ATS) were used to determine clinical relevance. Treatment was compared with guidelines published by the British Thoracic Society. In total, 51 patients were found from whom M. malmoense was isolated. Of these, 40 (78%) patients had pulmonary isolates and 32 (80%) of them met the ATS diagnostic criteria. Cavitary disease was most common (n = 28; 88%). Patients with pulmonary disease were mostly males, with an average age of 56 yrs and pre-existing chronic obstructive pulmonary disease. Cervical lymphadenitis was the most common extrapulmonary disease type. Adherence to treatment guidelines was poor. A good clinical response to treatment was observed in 70% and 73% of patients treated for pulmonary and extrapulmonary disease, respectively. In conclusion, M. malmoense is a clinically highly relevant NTM in The Netherlands causing serious pulmonary morbidity. Adherence to treatment guidelines is not satisfactory
Martin J Boeree - One of the best experts on this subject based on the ideXlab platform.
-
synergistic activity of rifampicin and ethambutol against slow growing nontuberculous mycobacteria is currently of questionable clinical significance
International Journal of Antimicrobial Agents, 2013Co-Authors: Jakko Van Ingen, Wouter Hoefsloot, Martin J Boeree, Johan W Mouton, Dick Van SoolingenAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n = 5), Mycobacterium chimaera (n = 6), Mycobacterium intracellulare (n = 4), Mycobacterium xenopi (n = 4), Mycobacterium malmoense (n = 3) and Mycobacterium simiae (n = 2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index ≤ 0.5. Rifampicin and ethambutol showed synergistic activity against the majority of M. avium (4/5), M. chimaera (5/6) and M. intracellulare (3/4) isolates and 1 of 2 eligible M. malmoense isolates. No synergistic activity was measured against M. xenopi and M. simiae. Synergy was neither universal for all species nor for all isolates of one species; it thus needs to be tested for rather than assumed. Even if this synergy exists in vivo, it is questionable whether the MICs to the combined drugs can be overcome by the drug exposure attained by current regimens at the recommended dosages. New dosing strategies for rifampicin and ethambutol should be studied to increase the exposure to these drugs and thus maximise their impact.
-
Mycobacterium riyadhense sp nov a non tuberculous species identified as Mycobacterium tuberculosis complex by a commercial line probe assay
International Journal of Systematic and Evolutionary Microbiology, 2009Co-Authors: Jakko Van Ingen, Martin J Boeree, Sahal Alhajoj, Fahad Alrabiah, Mimount Enaimi, Rina De Zwaan, Enrico Tortoli, Richard Dekhuijzen, Dick Van SoolingenAbstract:A non-chromogenic, slowly growing Mycobacterium strain was isolated from a maxillary sinus lavage from a symptomatic patient in Riyadh, Saudi Arabia. It was initially identified as a member of the Mycobacterium tuberculosis complex by a commercial line-probe assay. Its 16S rRNA, hsp65 and rpoB gene and 16S-23S internal transcribed spacer sequences were unique; phylogenetic analysis based on the 16S rRNA gene sequence groups this organism close to Mycobacterium szulgai and Mycobacterium malmoense. Its unique biochemical properties and mycolic acid profile support separate species status. We propose the name Mycobacterium riyadhense sp. nov. to accommodate this strain. The type strain is NLA000201958(T) (=CIP 109808(T) =DSM 45176(T)).
Ingen, J. Van - One of the best experts on this subject based on the ideXlab platform.
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
'Elsevier BV', 2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton † J.w., Soolingen D. VanAbstract:Contains fulltext : 117716.pdf (Publisher’s version ) (Closed access)A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
2013Co-Authors: Ingen, J. Van, Boeree M.j., Hoefsloot W., Mouton J.w., Soolingen D. VanAbstract:A key issue in the treatment of disease caused by slow-growing nontuberculous mycobacteria is the limited association between in vitro minimum inhibitory concentrations (MICs) of rifampicin and ethambutol alone and the in vivo outcome of treatment with these drugs. Combined susceptibility testing to rifampicin and ethambutol could provide a more realistic view of the efficacy of these drugs. In this study, Mycobacterium avium (n=5), Mycobacterium chimaera (n=6), Mycobacterium intracellulare (n=4), Mycobacterium xenopi (n=4), Mycobacterium malmoense (n=3) and Mycobacterium simiae (n=2) clinical isolates were selected and the MICs of rifampicin and ethambutol alone and in combination were measured using the Middlebrook 7H10 agar dilution method. Synergy was defined as a fractional inhibitory concentration index
-
Isolation of mycobacteria other than Mycobacterium avium from porcine lymph nodes
2010Co-Authors: Ingen, J. Van, Wisselink H.j., Solt-smits, C.b. Van, Boeree M.j., Soolingen D.Abstract:Mycobacterium avium causes lymphadenitis in pigs. This presents an economical burden, as these pigs meat is considered inappropriate for consumption. In humans, lymphadenitis due to nontuberculous mycobacteria (NTM) primarily affects children and is caused by a variety of NTM, though M. avium predominates. Mycobacterial culture was undertaken on lymph nodes of 107 slaughter pigs from a single pig farm. A high number of pigs with mycobacterial lymphadenitis were identified by culture. A commercial line probe assay and 16S rDNA gene sequencing were used to assess the frequency of disease due to mycobacteria other than M. avium. Forty-five pigs had mandibular lymph node samples yielding mycobacteria in culture. The majority yielded M. avium (39; 87%) only. One yielded M. avium and Mycobacterium palustre, five yielded only NTM other than M. avium (2 yielded Mycobacterium malmoense, 1 Mycobacterium bohemicum, 1 Mycobacterium heckeshornense and a possibly novel species related to Mycobacterium scrofulaceum, and 1 grew a possibly novel species related to M. palustre). Several NTM species other than M. avium were cultured from porcine lymph nodes. The species distribution shows interesting parallels with human NTM lymphadenitis. Molecular typing and environmental sampling studies are required to identify the sources of these infections
-
Isolation of mycobacteria other than Mycobacterium avium from porcine lymph nodes.
'Elsevier BV', 2010Co-Authors: Ingen, J. Van, Wisselink H.j., Solt-smits, C.b. Van, Boeree M.j., Soolingen D. VanAbstract:Contains fulltext : 87901.pdf (publisher's version ) (Closed access)Mycobacterium avium causes lymphadenitis in pigs. This presents an economical burden, as these pigs meat is considered inappropriate for consumption. In humans, lymphadenitis due to nontuberculous mycobacteria (NTM) primarily affects children and is caused by a variety of NTM, though M. avium predominates. Mycobacterial culture was undertaken on lymph nodes of 107 slaughter pigs from a single pig farm. A high number of pigs with mycobacterial lymphadenitis were identified by culture. A commercial line probe assay and 16S rDNA gene sequencing were used to assess the frequency of disease due to mycobacteria other than M. avium. Forty-five pigs had mandibular lymph node samples yielding mycobacteria in culture. The majority yielded M. avium (39; 87%) only. One yielded M. avium and Mycobacterium palustre, five yielded only NTM other than M. avium (2yielded Mycobacterium malmoense, 1Mycobacterium bohemicum, 1Mycobacterium heckeshornense and a possibly novel species related to Mycobacterium scrofulaceum, and 1 grew a possibly novel species related to M. palustre). Several NTM species other than M. avium were cultured from porcine lymph nodes. The species distribution shows interesting parallels with human NTM lymphadenitis. Molecular typing and environmental sampling studies are required to identify the sources of these infections
-
Clinical relevance of Mycobacterium malmoense isolation in The Netherlands.
'European Respiratory Society (ERS)', 2009Co-Authors: Hoefsloot W., Ingen, J. Van, Boeree M.j., W.c.m. De ,lange, Dekhuijzen P.n.r., Soolingen D. VanAbstract:Uncertainty exists about the clinical relevance of Mycobacterium malmoense isolation, especially in pulmonary samples. We therefore determined clinical relevance, treatment and outcome of M. malmoense isolation in The Netherlands. A retrospective medical file study was conducted for all patients in The Netherlands from whom Mycobacterium malmoense had been isolated between January 2002 and January 2006. Diagnostic criteria for nontuberculous mycobacterial (NTM) disease published by the American Thoracic Society (ATS) were used to determine clinical relevance. Treatment was compared with guidelines published by the British Thoracic Society. In total, 51 patients were found from whom M. malmoense was isolated. Of these, 40 (78%) patients had pulmonary isolates and 32 (80%) of them met the ATS diagnostic criteria. Cavitary disease was most common (n = 28; 88%). Patients with pulmonary disease were mostly males, with an average age of 56 yrs and pre-existing chronic obstructive pulmonary disease. Cervical lymphadenitis was the most common extrapulmonary disease type. Adherence to treatment guidelines was poor. A good clinical response to treatment was observed in 70% and 73% of patients treated for pulmonary and extrapulmonary disease, respectively. In conclusion, M. malmoense is a clinically highly relevant NTM in The Netherlands causing serious pulmonary morbidity. Adherence to treatment guidelines is not satisfactory
